Clinuvel Pharmaceuticals (UR9) Stock Statistics & Valuation Metrics

Clinuvel Pharmaceuticals has a market cap or net worth of CHF244.60M. The enterprise value is CHF272.15.

Clinuvel Pharmaceuticals has 50,427,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Clinuvel Pharmaceuticals ’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 10.40%.

The current PE Ratio of Clinuvel Pharmaceuticals is 12.2. Clinuvel Pharmaceuticals ’s PEG ratio is -2.72.

In the last 12 months, Clinuvel Pharmaceuticals had revenue of 94.02M and earned 33.92M in profits. Earnings per share was 0.68.

In the last 12 months, operating cash flow was 36.91M and capital expenditures -1.60M, giving a free cash flow of 35.31M billion.

Clinuvel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Clinuvel Pharmaceuticals upcoming earnings date is Feb 23, 2027, TBA (Confirmed).

Clinuvel Pharmaceuticals as a current ratio of 14.81, with Debt / Equity ratio of 0.71%

In the past 12 months, Clinuvel Pharmaceuticals has paid 13.74M in taxes.

Clinuvel Pharmaceuticals EV to EBITDA ratio is 12.02, with an EV/FCF ratio of 14.00.

Clinuvel Pharmaceuticals has CHF252.06M in cash and marketable securities with CHF1.94M in debt, giving a net cash position of CHF250.12M billion.

Gross margin is 43.11%, with operating margin of 43.11%, and net profit margin of 36.07%.

The average price target for Clinuvel Pharmaceuticals is CHF9.90, which is 11.43% higher than the current price. The consensus rating is Moderate Buy